• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Janssen Biotech Inc. - Articles and news items

ibrutinib

FDA grants Breakthrough designation to ibrutinib in cGVHD

Industry news / 1 July 2016 / Victoria White, Digital Content Producer

This marks the first time ibrutinib has been granted Breakthrough Therapy Designation for an indication beyond haematologic malignancies…

Tesaro

Janssen and Tesaro in niraparib collaboration and license agreement

Industry news / 8 April 2016 / Victoria White, Digital Content Producer

Tesaro will receive an upfront payment of $35 million, and is eligible to receive additional milestone payments of up to $415 million…

stelara

Janssen seeks approval of Stelara for Crohn’s disease

Industry news / 30 November 2015 / Victoria White

Stelara (ustekinumab), approved for the treatment of plaque psoriasis and active psoriatic arthritis in many countries, is a human monoclonal antibody that targets interleukin (IL)-12 and IL-23 cytokines…

Darzalex

FDA approves Darzalex for multiple myeloma

Industry news / 17 November 2015 / Victoria White

Darzalex (daratumumab) is the first human anti-CD38 monoclonal antibody (mAb) approved anywhere in the world…

yondelis

FDA approves Yondelis for liposarcoma and leiomyosarcoma

Industry news / 26 October 2015 / Victoria White

The approval was based on recently published clinical efficacy and safety data from a Phase 3 study which evaluated Yondelis versus the chemotherapy agent dacarbazine…

ibrutinib

Supplemental New Drug Application for ibrutinib submitted to FDA

Industry news / 14 September 2015 / Victoria White

The supplemental New Drug Application has been submitted for front-line use of ibrutinib in patients with chronic lymphocytic leukaemia…

Johnson & Johnson logo

IMBRUVICA™ (ibrutinib) now approved in the U.S. for patients with chronic lymphocytic leukemia who have received at least one prior therapy

Industry news / 13 February 2014 / Johnson & Johnson

Janssen Biotech, Inc. announced the U.S. Food and Drug Administration has approved IMBRUVICA™ (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy…

Janssen Pharmaceuticals Logo

IMBRUVICA™ (ibrutinib) capsules now approved in the U.S. for Mantle Cell Lymphoma patients who have received at least one prior therapy

Industry news / 13 November 2013 / Johnson & Johnson

Single-agent oral therapy is one of the first medications to be approved via the U.S. Food and Drug Administration’s Breakthrough Therapy Designation Pathway…

Abbott logo

Abbott to collaborate with Janssen and Pharmacyclics

Industry news, News / 21 February 2013 / Abbott

Abbott will collaborate with Janssen Biotech and Pharmacyclics to explore the benefits of Abbott’s proprietary FISH technology…

Janssen Pharmaceuticals Logo
Janssen Pharmaceuticals Logo

Janssen Biotech, Inc. announces collaborative development and worldwide license agreement for investigational anti-cancer drug, PCI-32765

Industry news, News / 8 December 2011 / Johnson & Johnson

Compound in development for multiple B-cell hematologic malignancies…

Janssen Pharmaceuticals Logo

FDA Advisory Committee recommends approval of Remicade®

Industry news, News / 21 July 2011 /

The Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. FDA recommended the approval of REMICADE® (infliximab)…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +